Cargando…

Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort

INTRODUCTION: The mechanisms leading to chronic kidney disease (CKD) in patients with idiopathic inflammatory myopathies (IIMs) are poorly understood. We assessed the prevalence of subclinical renal injury in patients with IIMs, through elevation in biomarker levels of tubular injury and fibrosis (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Conticini, Edoardo, Naveen, R., Sen, Parikshit, Singh, Mantabya, Rathore, Upendra, Anuja, Anamika Kumari, Rai, Mohit Kumar, Yadav, Brijesh, Prasad, Narayan, Agarwal, Vikas, Gupta, Latika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325640/
https://www.ncbi.nlm.nih.gov/pubmed/37425322
http://dx.doi.org/10.3389/fmed.2023.1127657
_version_ 1785069263475703808
author Conticini, Edoardo
Naveen, R.
Sen, Parikshit
Singh, Mantabya
Rathore, Upendra
Anuja, Anamika Kumari
Rai, Mohit Kumar
Yadav, Brijesh
Prasad, Narayan
Agarwal, Vikas
Gupta, Latika
author_facet Conticini, Edoardo
Naveen, R.
Sen, Parikshit
Singh, Mantabya
Rathore, Upendra
Anuja, Anamika Kumari
Rai, Mohit Kumar
Yadav, Brijesh
Prasad, Narayan
Agarwal, Vikas
Gupta, Latika
author_sort Conticini, Edoardo
collection PubMed
description INTRODUCTION: The mechanisms leading to chronic kidney disease (CKD) in patients with idiopathic inflammatory myopathies (IIMs) are poorly understood. We assessed the prevalence of subclinical renal injury in patients with IIMs, through elevation in biomarker levels of tubular injury and fibrosis (NGAL, KIM1, Activin A, CD163, and Cys-c), and assessed differences between subtypes of IIMs, and the effect of disease activity and duration. MATERIALS AND METHODS: Clinical data, core set measures, sera and urine were prospectively collected from all patients enrolled in the MyoCite cohort from 2017 to 2021. Twenty healthy subjects (HC) and 16 patients with acute kidney injury (AKI) were included as controls. Baseline and follow up data for IIMs were included. Enzyme-linked immunosorbent assay (ELISA) was used to measure urine NGAL (Human Lipocalin-2/NGAL Duoset ELISA, Cat no: DY1757), KIM1 (Human TIM-1/KIM 1/HAVCR Duoset ELISA, Cat.no: DY1750B), Activin A (Human Activin A Duoset ELISA, Cat no: DY338), CD163 (Human CD163 Duoset ELISA,Cat no: DY1607-05), and Cys-c (Human Cystatin C Duoset ELISA, Cat. no.: DY1196) levels, while eGFR (unit mL/min/1.73 m2) was calculated by the Cockcroft-Gault formula and CKD-EPI formula. RESULTS: Analysis of 201 visits of 110 adult patients with IIMs indicated higher normalized biomarker levels compared to HCs, and comparable to patients with AKI, with the exception of NGAL, which was higher in the AKI group. Notably 72 (49%) patients with IIMs had eGFR<90; the levels of the 5 biomarkers were comparable between active and inactive IIMs, and different subtypes of IIMs. Similarly, a poor correlation between urine biomarker levels and core set measures of activity and damage was found. Changes in biomarker levels on follow-up did not correlate with eGFR changes. DISCUSSION: This exploratory analysis of urinary biomarkers identified low eGFR and elevated biomarkers of CKD in nearly half of the patients with IIMs, comparable to patients with AKI and higher than HCs, indicative of potential renal damage in IIMs that may have a lead to complications in other systems.
format Online
Article
Text
id pubmed-10325640
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103256402023-07-07 Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort Conticini, Edoardo Naveen, R. Sen, Parikshit Singh, Mantabya Rathore, Upendra Anuja, Anamika Kumari Rai, Mohit Kumar Yadav, Brijesh Prasad, Narayan Agarwal, Vikas Gupta, Latika Front Med (Lausanne) Medicine INTRODUCTION: The mechanisms leading to chronic kidney disease (CKD) in patients with idiopathic inflammatory myopathies (IIMs) are poorly understood. We assessed the prevalence of subclinical renal injury in patients with IIMs, through elevation in biomarker levels of tubular injury and fibrosis (NGAL, KIM1, Activin A, CD163, and Cys-c), and assessed differences between subtypes of IIMs, and the effect of disease activity and duration. MATERIALS AND METHODS: Clinical data, core set measures, sera and urine were prospectively collected from all patients enrolled in the MyoCite cohort from 2017 to 2021. Twenty healthy subjects (HC) and 16 patients with acute kidney injury (AKI) were included as controls. Baseline and follow up data for IIMs were included. Enzyme-linked immunosorbent assay (ELISA) was used to measure urine NGAL (Human Lipocalin-2/NGAL Duoset ELISA, Cat no: DY1757), KIM1 (Human TIM-1/KIM 1/HAVCR Duoset ELISA, Cat.no: DY1750B), Activin A (Human Activin A Duoset ELISA, Cat no: DY338), CD163 (Human CD163 Duoset ELISA,Cat no: DY1607-05), and Cys-c (Human Cystatin C Duoset ELISA, Cat. no.: DY1196) levels, while eGFR (unit mL/min/1.73 m2) was calculated by the Cockcroft-Gault formula and CKD-EPI formula. RESULTS: Analysis of 201 visits of 110 adult patients with IIMs indicated higher normalized biomarker levels compared to HCs, and comparable to patients with AKI, with the exception of NGAL, which was higher in the AKI group. Notably 72 (49%) patients with IIMs had eGFR<90; the levels of the 5 biomarkers were comparable between active and inactive IIMs, and different subtypes of IIMs. Similarly, a poor correlation between urine biomarker levels and core set measures of activity and damage was found. Changes in biomarker levels on follow-up did not correlate with eGFR changes. DISCUSSION: This exploratory analysis of urinary biomarkers identified low eGFR and elevated biomarkers of CKD in nearly half of the patients with IIMs, comparable to patients with AKI and higher than HCs, indicative of potential renal damage in IIMs that may have a lead to complications in other systems. Frontiers Media S.A. 2023-06-22 /pmc/articles/PMC10325640/ /pubmed/37425322 http://dx.doi.org/10.3389/fmed.2023.1127657 Text en Copyright © 2023 Conticini, Naveen, Sen, Singh, Rathore, Anuja, Rai, Yadav, Prasad, Agarwal and Gupta. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Conticini, Edoardo
Naveen, R.
Sen, Parikshit
Singh, Mantabya
Rathore, Upendra
Anuja, Anamika Kumari
Rai, Mohit Kumar
Yadav, Brijesh
Prasad, Narayan
Agarwal, Vikas
Gupta, Latika
Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort
title Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort
title_full Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort
title_fullStr Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort
title_full_unstemmed Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort
title_short Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort
title_sort renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the myocite cohort
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325640/
https://www.ncbi.nlm.nih.gov/pubmed/37425322
http://dx.doi.org/10.3389/fmed.2023.1127657
work_keys_str_mv AT conticiniedoardo renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT naveenr renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT senparikshit renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT singhmantabya renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT rathoreupendra renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT anujaanamikakumari renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT raimohitkumar renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT yadavbrijesh renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT prasadnarayan renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT agarwalvikas renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort
AT guptalatika renalinjurybiomarkersandmyositisanunderstudiedaspectofdiseaseprospectivestudyinthemyocitecohort